Le Lézard
Classified in: Covid-19 virus

$250 Billion Worldwide Mobile Health Monitoring, Diagnostic Devices and Services Industry to 2027 - Impact of COVID-19 - ResearchAndMarkets.com


The "Mobile Health Monitoring, Diagnostic Devices and Services - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The publisher brings years of research experience to the 6th edition of this report. The 118-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Mobile Health Monitoring, Diagnostic Devices and Services Market to Reach $250.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Mobile Health Monitoring, Diagnostic Devices and Services estimated at US$23.1 Billion in the year 2020, is projected to reach a revised size of US$250.5 Billion by 2027, growing at a CAGR of 40.6% over the analysis period 2020-2027. Cardiac Monitors, one of the segments analyzed in the report, is projected to record a 41.8% CAGR and reach US$46.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Diagnostic Device segment is readjusted to a revised 33.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7 Billion, While China is Forecast to Grow at 38.2% CAGR

The Mobile Health Monitoring, Diagnostic Devices and Services market in the U.S. is estimated at US$7 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$39.7 Billion by the year 2027 trailing a CAGR of 38.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 36.9% and 34.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 27.4% CAGR.

Diabetes Management Devices Segment to Record 47% CAGR

In the global Diabetes Management Devices segment, USA, Canada, Japan, China and Europe will drive the 46.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$6.9 Billion in the year 2020 will reach a projected size of US$101.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$30.8 Billion by the year 2027.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/oy3f0b


These press releases may also interest you

at 01:05
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...

24 avr 2024
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024. Highlights for the Quarter: Net income available to common...

24 avr 2024
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...

24 avr 2024
Teradyne, Inc. reported revenue of $600 million for the first quarter of 2024 of which $412 million was in Semiconductor...



News published on and distributed by: